Author: ModernMedia

Categories : Environmental Effects Obstetrics & GynaecologyTags :

Artificial Light Changes Menstrual Synchronisation with the Moon

On By ModernMedia

There is no question that the moon has a significant influence on Earth. Its gravitational pull affects the planet and moves water masses in the daily rhythm of ebb and flow (tides) – this point is undisputed. More difficult to answer is the question of whether the same gravitational force also affects life on Earth, especially the human organism. And the discussion becomes even more complicated when it comes to how the fluctuating brightness of the Earth’s satellite between full and new moon affects humans.

A research team led by Julius-Maximilians-Universität Würzburg (JMU) has now presented new findings on this topic. Its conclusion: “We show that synchronisation with the moon has decreased significantly since the introduction of LEDs and the increasing use of smartphones and screens of all kinds,” explains Charlotte Förster. The Würzburg chronobiologist recently headed the Department of Neurobiology and Genetics; she now conducts research there as a senior professor.

Comparing Records from two Centuries

For their study, now published in the journal Science Advances, Förster and her team analysed long-term menstrual records of women from the past 50 years. “The results showed that the menstrual cycles of women whose records were made before the introduction of light-emitting diodes in 2010 and the widespread use of smartphones were significantly synchronised with the cycle of the full and new moon,” says Förster, describing the key finding. After 2010, the cycles were mostly only synchronized in January, when the gravitational forces between the moon, sun, and Earth are at their highest.

The scientists therefore hypothesize that humans have an internal moon clock that can be synchronised to the lunar cycle by natural night light and gravitational forces. However, the coupling of the moon clock to the lunar cycle in humans is impaired by increasing nighttime illumination from artificial light.

Other Studies Support the Moon Clock Hypothesis

“Moon clocks are widespread in marine organisms, but have not yet been proven in humans,” explains Charlotte Förster. In fact, many species synchronize their reproductive behaviour with a specific phase of the lunar cycle in order to increase reproductive success. The human menstrual cycle also has a similar duration to the lunar cycle, at approximately 29.5 days, and recent studies also suggest at least temporary synchronicity between the menstrual and lunar cycles.

The influence of the moon on the female cycle remains controversial. “It is completely unclear how such a lunar clock can be synchronised by the small cyclical changes in gravity between the Earth and the moon,” says Förster. The findings now published are consistent with results from sleep research and psychiatry.

For example, studies by two chronobiologists, Basel researcher Christian Cajochen and Washington biologist Horacio de la Iglesia, show that people sleep significantly less around the full and new moon than at other times. “Interestingly, this also applies to city dwellers, where nighttime city lighting is much brighter than the light of the full moon,” says the chronobiologist. And US psychiatrist Thomas Wehr has concluded that people with bipolar disorder are more likely to switch between mania and depression around the full and new moon.

Artificial Light Disrupts Synchronisation

Taken together, these findings suggest that humans can respond not only to moonlight, but also to the gravitational cycles caused by the moon, according to the Würzburg research team. “However, our study shows that increased exposure to artificial light severely impairs the synchrony between the menstrual cycle and the lunar cycle,” explains Charlotte Förster.

According to this, artificial light at night not only “outshines” the natural moonlight cycles, but also shortens the length of the menstrual cycle. However, since continuous synchronization is only possible if the length of the cycle is close to the lunar cycle, this shortening in turn reduces the likelihood of synchronization.

A High Proportion of Blue Light Increases the Effect

Anyone wondering why the introduction of LEDs and the increasing use of smartphones have this effect – after all, artificial lighting has been around for a long time, from gas lanterns to incandescent light bulbs – will find an explanation in Charlotte Förster’s words: “LEDs have much higher energy than gas lanterns and light bulbs. In addition, they have a high proportion of blue light, to which our photoreceptors in the eye are particularly sensitive.” That is why LED light has a much stronger effect on humans than previous light sources.

And even though Charlotte Förster and her team were able to clearly demonstrate that the synchronization of the female menstrual cycle with the moon is weakened by LEDs, smartphones, and screens of all kinds, there is one small caveat when interpreting these results: “Our findings show a correlation between these two phenomena. We were unable to establish a causal link,” says the scientist.

In principle, the study now published is basic research. Nevertheless, a potential benefit emerges from the evaluation of the data: “Since period length appears to be a possible age-dependent marker for female fertility, our findings could be relevant not only for human physiology and behaviour, but also for fertility and contraception,” says Charlotte Förster.

Source: University of Würzburg

Categories : Environmental EffectsTags :

New Research Calls for Global Action on Micro- and Nanoplastics in the Atmosphere

On By ModernMedia
Photo by FLY:D on Unsplash

Scientists at The University of Manchester are calling for the creation of a global network of air monitoring stations to track the movement of airborne plastic pollution, which may be travelling further and faster around the planet than previously thought.

In a new review, published in the journal Current Pollution Reports, the researchers have examined the current scientific research on how tiny plastic fragments – called micro and nanoplastics – enter the air, where they come from, and the mechanisms that transport them across vast distances.

The study reveals significant gaps in knowledge and understanding of airborne plastic pollution, driven by inconsistent measurement techniques, limited data, oversimplified simulations, and gaps in understanding atmospheric cycling mechanisms.

One key uncertainty is the scale of plastic entering the atmosphere. Current estimates vary wildly – from less than 800 tonnes to nearly 9 million tonnes per year – making it difficult to assess the true global impact. It also remains unclear whether the dominant contributors are land-based, such as road traffic, or marine based, such as sea spray.

Such large uncertainties raise the concern that airborne plastics, which pose potential risks to human and environmental health, may have a more extensive presence and influence than previously captured by current monitoring and simulation systems.

“The scale of uncertainty around how much plastic is entering our atmosphere is alarming. Plastic pollution can have serious consequences for human health and ecosystems, so in order to assess the risks, we need to better understand how these particles behave in the atmosphere. If we want to protect people and the planet, we need better data, better models, and global coordination.”

Lead author Zhonghua Zheng, Co-Lead for Environmental Data Science & AI at Manchester Environmental Research Institute (MERI) and Lecturer in Data Science & Environmental Analytics at The University of Manchester

Each year, the world produces over 400 million tonnes of plastic, with a significant proportion ending up as waste. Over time, these plastics breaks down into microscopic particles called microplastics (less than 5mm) and nanoplastics (smaller than 1 micron), which are increasingly being found in the air we breath, oceans and soil. These particles can move thousands of miles within days and have even remote regions like polar ice zones, desserts and remote mountain peaks.

While our understanding of the problem has grown rapidly, limited real-world data, inconsistent sampling methods, and computer models that oversimplify how plastic behaves in the air, means that key questions remain unanswered.

To address these concerns, the authors are calling for future research efforts to focus on three critical areas:

  • Expanding and standardising global observation networks
  • Improving and refining atmospheric modelling
  • Harnessing the power of artificial intelligence (AI)

They say this integrated approach could transform how we understand and manage the plastic pollution crisis.

“By adopting this integrated approach, we can fundamentally transform how we understand and manage this emerging threat. AI can play a powerful role in analysing data and simulating plastic movement, it can help make sense of fragmented datasets, detect hidden patterns, and integrate information from multiple sources – but it needs good quality data to work with. All of these areas must work hand in hand to manage this emerging threat and shape effective global pollution strategies.”

Fei Jiang, PhD researcher at The University of Manchester

Source: University of Manchester

Categories : Respiratory Diseases Substance UseTags :

Inhaling Cannabis May Greatly Increase Risk of Lung Disease

On By ModernMedia
Photo by Rodnae Productions on Pexels

For those looking to reduce their chances of developing lung disease, say experts at UC San Francisco, then it may be smart to avoid inhaling cannabis.

A new study in the Journal of General Internal Medicine found that inhaling marijuana every day is associated with a 44% increased chance of developing asthma. It also increases the odds of developing a common set of lung diseases known as chronic obstructive pulmonary disease (COPD) by 27%.

The risk of COPD, which includes emphysema and chronic bronchitis, may be understated. The disease takes decades to develop, and the researchers did not have detailed information on how long people in the study had been using cannabis.

Researchers defined “inhaling” as smoking, vaping, and so-called “dabbing,” which involves breathing in the vapors of concentrated marijuana. The study found an association between elevated risks to a person’s lungs and doing any of those things with cannabis even for those who had never smoked cigarettes.

For those who never smoked cigarettes, inhaling marijuana every day was linked to a 51% increased likelihood of developing asthma. The association with COPD was also elevated, but it was not statistically significant.

The study is the largest yet to examine the association between inhaling cannabis and risks to respiratory health among people who have not smoked cigarettes. Of the 380 000 adult participants, nearly 222 000 had never smoked tobacco. The data comes from the Behavioral Risk Factor Surveillance System, a national survey by the Centers for Disease Control and Prevention (CDC).

Experts say the broad legalization of marijuana across much of the country and the perception that it is healthier than tobacco has led people to minimize the risks.

“The message about smoking tobacco being bad for you has gotten out there, but for cannabis, it’s much less clear,” said Alison Rustagi, MD, PhD, assistant professor at UCSF and first author of the paper.

“If people are looking to reduce their likelihood of developing a chronic lung disease, they should not start using cannabis,” she said. “And if they already smoke cannabis, they should do it less often.”

Source: University of California – San Francisco

Categories : Ethics and Law Mental HealthTags :

Untangling the Argument Around Prenatal Paracetamol and Autism

On By ModernMedia
Photo by SHVETS production

On Monday 22 September, US President Donald Trump made a widely-publicised announcement that paracetamol (acetaminophen/Tylenol) during pregnancy was confirmed as causing autism spectrum disorder (ASD). The claim – backed by a single, rather dodgy study – brings to a head long-standing concerns about the apparent, well-documented increase in ASD rates. QuickNews dives into the controversy to find out if there is any validity to the claims.

President Trump said, “With Tylenol, don’t take it. Don’t take it. And if you can’t live, if your fever is so bad, you have to take one because there’s no alternative to that, sadly,” adding that other medicines such as aspirin were also “proven bad”.

The announcement had been expected for some time and doctors, scientists and medical organisations were quick to respond. The president of the American College of Obstetricians and Gynecologists stated that the paracetamol–ASD claim “is not backed by the full body of scientific evidence and dangerously simplifies the many and complex causes of neurologic challenges in children”.

At the very least, such an announcement will causing pregnant women to second-guess their taking one of the few over-the-counter pain medications widely regarded as safe during pregnancy. In 2017, the X account for Tylenol stated “We actually don’t recommend using any of our products while pregnant.” But a major pharmaceutical manufacturer would want to protect itself from liability as broadly as possible. The politically-charged nature of the announcement has also seen pregnant women making TikTok videos of themselves apparently taking paracetamol (often with no reason to).

It is generally accepted that ASD is caused by a combination of genetics and environmental factors. About 1000 genes are believed to be related to ASD. And there is a very long list of possible risk factors, with an uncertain risk contribution: “Non-genetic factors mediating ASD risk could include parental age, maternal nutritional and metabolic status, infection during pregnancy, prenatal stress, and exposure to certain toxins, heavy metals, or drugs.”

Study validity questioned

To date, paracetamol during pregnancy had generally been linked by a number of poorly powered studies to a wide variety of outcomes: in addition to ASD, asthma, lower performance intelligence quotient (IQ), shorter male infant anogenital distance (predicting poor male reproductive potential), neurodevelopmental problems (gross motor development, communication), attention-deficit/hyperactivity disorder, poorer attention and executive function, and behavioural problems in childhood. A study of nearly 2.5 million children, the largest and most comprehensive do date, found a slight link for paracetamol exposure and autism – which vanished when controlled for sibling exposure (representing shared environment).

Before President Trump’s announcement, news releases on a review making the link were published some weeks before – QuickNews even covered it. The review, published in Environmental Health, selected certain related studies using the ‘Navigation Guide’ methodology – a non-quantitative methodology for the narrow use of inferring health impacts from environmental toxins, but was nevertheless used for pharmaco-epidemiology and teratology. According to Nathan A. Schacthman, legal counsel for scientific matters, the study has serious conflicts of interest: for example, last author Andrea A. Baccarelli is an environmental epidemiologist who has been involved with a lawsuit against manufacturers and sellers of paracetamol. In that lawsuit, his claims were thrown out on the basis of not having sufficient validity, including cherry-picked data and over-generalisation to distinct disorders (such as grouping attention-deficit hyperactivity disorder [ADHD] and other neurodevelopmental disorders). In addition, the study also made misleading claimed about being funded by the National Institutes for Health (NIH). Finally, although this is not mentioned by Schacthman, Robert F. Kennedy Jr. is also an environmental lawyer.

What’s this about a ‘cure’ for autism?

The bombshell announcement by President Trump came with an another bombshell announcement that there was ‘cure’ for autism. The cure is allegedly leucovorin – which sounds very impressive to the non-medical public. But leucovorin is merely folinic acid, which is a vitamer of plain old folic acid – aka vitamin B9. Folinic acid is on the World Health Organization’s essential medicines list. On the same Monday, the US Food and Drug Administration approved it for the treatment of ASD in children – bypassing the normal review process.

Can a simple medication – or rather, supplement – really ‘cure’ ASD, an extremely complex neurological disorder? The NIH funds about $300 million in ASD research annually, nearly double the amount in 2011. If anything, this has echoes of President Trump’s touting of hydroxychloroquine as a now-discredited cure for COVID in the height of the pandemic. It might indeed be beneficial if a patient had a bout of malaria and COVID at the same time, but was rapidly discredited.

The largest controlled study for the use of folinic acid supplementation plus usual care found only a modest ~1 point increase in the Childhood Autism Rating Scale (CARS) compared to usual care plus placebo.

There are also concerns about potential conflicts of interest. One of the manufacturers of folinic acid, iHerb, had the celebrity heart doctor Mehmet Oz as an investor, and is now the administrator for the Centers for Medicare & Medicaid Services (CMS), served until recently. CMS has however denied that Dr Oz will receive any financial reward from this.

But why are autism rates on the rise?

There are a few good explanations about why the rate of autism diagnoses is increasing, which do not depend on the addition of some new environmental variable. The first and most obvious is that there is increased awareness of this, and more referrals for assessment. A second reason is that the guidelines for diagnosis have become a lot less stringent. The definition of autism diagnoses, unlike schizophrenia, has drifted over time, with more “normal” people being likely to be diagnosed. The DSM-III of 1980 had more stringent criteria, for example, an individual needed to exhibit “a pervasive lack of responsiveness to other people” [emphasis added].

Introduced from 1994, the DSM-IV had broader criteria, and folded Asperger disorder into ASD. With the introduction of the DSM-V, new diagnoses were curbed – for a time. This is because about 20% of the children diagnosed with ASD under DSM-IV-TR would not have received one under the DSM-V. The DSM-V relaxed the criteria for language delay, co-occurrence, and IQ, making it easier for borderline cases to qualify for a diagnosis.

Another underappreciated element is that of social contagion. If parents know a family with a child with ASD, they may be more likely to seek a diagnosis. One study from California showed that ASD diagnoses were more likely the more other ASD diagnoses under one kilometre away.

Back to square one

Considering the weakness of the cited studies, the difficulty of explaining ASD, the underlying social phenomenon of shifting diagnostic thresholds and increased awareness, it seems as though these announcements are mostly without substance. In amidst the headline-grabbing news, the NIH quietly announced the launch of a $50 million initiative into the causes of ASD.

According to the news release, the NIH will fund 13 projects “that draw on genomic, epigenomic, metabolomic, proteomic, clinical, behavioral and autism services data. These projects will integrate, aggregate and analyze existing data resources, generate targeted new data and validate findings through independent replication hubs.”

With this in mind, it really doesn’t look like paracetamol is the singular, mysterious controllable risk factor for ASD rates that President Trump and Robert F. Kennedy Jr have made it out to be. Maybe paracetamol use simply reflects infection, or some other related factor.

Categories : Allergies Lab Tests and ImagingTags :

From Symptoms to Solutions: Professional Testing Can Reveal Hidden Allergens

On By ModernMedia

As spring arrives in South Africa, many people experience their most challenging allergy season. However, while pollen-filled air triggers obvious seasonal symptoms, allergies extend far beyond springtime discomfort, affecting millions year-round through food sensitivities, skin reactions, and environmental triggers.

“Spring allergies are usually just the tip of the iceberg,” says Tyron Hansen, Business Development Manager at BioSmart Lab. “You wake to spring sunshine and nature in full bloom, but instead of enjoying it, you’re shut inside with tissues and antihistamines. Meanwhile, your stomach acts up after breakfast, and that mysterious rash on your arms is back. Sound familiar?”

Hansen explains that many people assume that their symptoms stem from a single source, like pollen or food preservatives. However, BioSmart Lab’s test results often reveal they’ve actually been living with multiple triggers they never connected to their symptoms.

Why It’s Worth Looking Deeper

Professional allergen tests measure specific antibodies in your blood to identify how your body reacts to different substances. This matters because what looks like “seasonal” hay fever might actually be a mix of environmental, food, and even skin-related triggers.

“Our immune systems are like complicated alarm systems,” explains Hansen. “They go off loudly, but without proper testing, you only hear the siren – you don’t see what’s actually setting it off.”

A major source of confusion is the difference between allergies and intolerances. Both of which can make you feel unwell, but function very differently:

  • Allergies: They set off the immune system through immunoglobulin E (IgE) antibodies, causing anything from a runny nose or itchy eyes to potentially life-threatening anaphylaxis, often within minutes of exposure.
  • Intolerances: These don’t set off your immune system, but they can still cause digestive discomfort like bloating or nausea, and while not dangerous, they can nevertheless affect daily life.

“Knowing which is which can be the key to finally feeling better,” he adds.

Everyday Triggers You Might Be Missing

Allergies aren’t always obvious or seasonal. Many people live with daily discomfort without realising what’s behind it. Hansen provides some of the most common sources of ongoing allergic reactions.

  • Environmental triggers: Dust mites, mould spores, pet dander, and certain plants can cause year-round congestion, itchy eyes, or skin flare-ups.
  • Food sensitivities: That heavy, bloated feeling after meals could point to, for example, wheat, rice and corn sensitivity, or even certain food combinations.
  • Skin reactions: Chronic eczema or rashes are sometimes triggered by hidden allergens, not simply “sensitive skin.”
  • Allergic clues in children: Kids often can’t articulate their symptoms. What might appear to be frequent colds, skin rashes, or trouble concentrating could be subtle signs of allergies.

“Trying to figure out if your symptoms are caused by allergens through elimination diets, behavioural adjustments, or symptom tracking can take months and still leave you without answers, notes Hansen. “Blood-based testing provides a faster alternative by measuring IgE antibodies – the proteins your immune system releases when it detects threats.”

Taking Back Control

BioSmart Lab’s advanced blood panels analyse these IgE proteins across multiple allergens simultaneously. These tests can be purchased online and provide accurate, quantitative results without the risk of sparking reactions or being influenced by medication use.

Some people discover that they need to remove wheat to manage food allergies. Others learn that their “pet allergy” is actually a dust mite sensitivity. Parents often find their child’s mid-afternoon meltdowns are directly linked to specific food triggers at lunch.

“The goal isn’t just to manage symptoms – it’s to restore people’s quality of life,” emphasises Hansen. “Once you understand what your body is reacting to, you can move from frustrating guesswork to making informed choices, giving you control of your health back,” he concludes.

For more information about BioSmart’s allergy testing options, visit https://biosmart.com/allergy-tests/.

Categories : HIVTags :

Response to Aid Cuts and HIV Prevention Injections Dominate Discussions at SA AIDS Conference

On By ModernMedia
Photo by Sergey Mikheev on Unsplash

By Ufrieda Ho

A dire picture for HIV/Aids funding emerged at the 12th South African AIDS Conference, raising the call for resilience, adapting and also for government to raise its game.

The what-next of South Africa’s HIV response will have to be centred on getting back to basics, leveraging on advances in treatment options and learning fast about adapting in a world without US aid for health services.

These were among the key takeaways from speakers at a plenary session at the 12th Southern African Aids Conference held in Kempton Park last week.

Professor Linda-Gail Bekker, executive officer of the Desmond Tutu Health Foundation, in her address took stock of “the incredible devastation around the world” from the virtual overnight shutting off of funds and human resources as Donald Trump returned to the US presidency in January 2025.

“It was $460 million into the wood chipper for us. And the worrying thing is that it could take us back to the harrowing scenes of 2000 [the height of Aids deaths in the country],” she said.

This comes against what she called the two largest challenges for South Africa’s HIV response: sub-optimal 12-month retention in care and viral suppression. Meaning the struggle to keep patients on treatment beyond a year and helping them stay on antiretrovirals that reduce the amount of virus in the body to a minimum.

The picture painted by Bekker and others is bleak, with much uncertainty remaining as to how South Africa might plug the funding holes left by the abrupt US aid cuts.

Bekker shared research by the Health Economics and Epidemiology Research Office (HE²RO), a division of the Wits Health Consortium at the University of the Witwatersrand. Their research shows that the fallout in the next three years could see South Africa experience a 29% to 56% increase in new HIV infections, or an additional 150 000 to 295 000 cases by 2028. Unless the South African government is able to take over services, there could be a 33% to 38% increase, or an additional 56 000 to 65 000 AIDS-related deaths in that period. (Spotlight previously reported on the HE²RO modelling in more detail here.)

The modelling also suggests that government will need additional funding of between $620 million and $1.4 billion (roughly R10 billion to R24 billion) between 2025 and 2028 to replace the local services that received US government funding.

In July, Treasury allocated R763 million in emergency funding to fill the gap, a fraction of what the HE²RO researchers estimate is needed. In addition, the Gates Foundation and the Wellcome Trust pledged R100 million each for research to the South African Medical Research Council on condition that the South African government doubled their contributions, which government committed to over three years. This added up to an R600 million bailout for research, also a fraction of the amount of research funding that has been lost.

The shortfall remains massive. Last year, Pepfar (United States President’s Emergency Funds for AIDS Relief) funds flowing to South Africa totalled over R7.5 billion.

Calls for greater transparency

Throughout the conference, there was also strong calls from attendees and speakers for government to be more transparent about its plans to mitigate the funding cuts and to provide credible data and information about monitoring and measuring of the success of their interventions. This includes details on how it plans to provide all stable patients with enough medicines for six months at a time. Such multi-month supplies mean people have to travel less to collect medicines, thus making it easier to stay on them. Rollout of multi-month dispensing has been very uneven across the country.

Questions were also raised over a lack of full transparency regarding the price of lenacapavir, a breakthrough HIV prevention injection that provides six months of protection per shot. As we recently reported, the South African government will be paying $60 per person per year for the jab, with other donors paying the rest – it is not publicly known how much this “rest” is. The deal was setup by the Global Fund to Fight AIDS, Tuberculosis and Malaria, Gilead Sciences – the company that makes lenacapavir – and several private donors. Last week, Spotlight published an op-ed in which activists questioned the lack of full transparency about the price.

Dr Sandile Buthelezi, director-general for the National Department of Health, told attendees about the possibility of bringing forward the rollout date for lenacapavir from April next year, to possibly as soon as November this year. He did not answer questions about the price negotiations. He did however confirm that negotiations with The Global Fund has seen them commit to ringfencing US$29 million for procurement of lenacapavir over the next two and a half years.

Doing more with less

Having to do more with less, Bekker said at the conference, will mean the need to build a “resilience bridge”. For her, this means preserving the “two most important interventions” of providing continued access to antiretroviral treatment and to HIV prevention treatments – both long-acting injections and prevention pills.

She added that it also means better efforts to reach the population of people living with HIV who have been diagnosed but are not on treatment. In February 2025, government launched its ‘Close the Gap’ campaign aimed at placing an additional 1.1 million people on treatment by the end of this year. Bekker said the number of people living with HIV who are not on treatment is closer to 2 million people. According to Thembisa, the leading mathematical model of HIV in the country, of the roughly eight million people living with HIV in South Africa, around 6.2 million are on treatment.

How South Africa is progressing against the 1.1 million target is not clear. Figures previously shared by Health Minister Dr Aaron Motsoaledi indicated that over half a million people had been initiated on treatment in a matter of months. This raised eyebrows since, on the face of it, it means that people had been started on treatment this year more quickly than at any other time in South Africa’s HIV response. It also wasn’t clear whether the number of people who had stopped treatment had been subtracted from the number starting treatment. Questions Spotlight previously sent to the health department seeking clarification of the numbers went unanswered. Similar questions were also raised in an open letter and an op-ed published by Spotlight and GroundUp. As yet, Spotlight has not seen answers to the questions raised about the numbers shared by the Minister.

“We need to make services [more] amenable to retention so it means multi-month dispensing and differentiated care,” Bekker said. Differentiated care refers to treating people differently based on their needs – for example by not requiring healthy people living with HIV to visit the clinic as often as sicker people.

“Bad policies that reflect ideology and bias, mean the most vulnerable are deterred from assessing the services they need, and this includes our key populations,” she added of the challenges that people like sex workers, members of the LGBTQI+ community and people who use drugs face in clinics where they are judged, harassed or discriminated against.

Dr Lise Jamieson, a senior researcher at HE²RO, echoed Bekker’s sentiments and said a first priority remains to arrest any backsliding of care as South Africa restructures its HIV programme to match the money it has currently. “It is clear that the one thing that we absolutely cannot drop is our HIV treatment programme – it saves lives,” she said.

For Yvette Raphael, the co-founder and co-director of Advocacy for the Prevention of HIV and Aids (APHA), the undergirding socio-economic factors that have given HIV its stranglehold in South Africa remain largely unchanged.

She said: “I am one of the people who are ageing with HIV and suffering from other non-communicable diseases that come with this”, highlighting the need to address the evolving nature of HIV in the country and the need to address it alongside conditions such as diabetes and heart disease.

But she added that it is still teen girls and young women who are at a disproportionately high risk of acquiring HIV. Her message was for better youth-targeted responses that are community-level responses not top-down strategies.

“Make HIV a priority sustained by local and district government structures, not up here in our national and province centres,” she said.

“Make HIV prevention harder to ignore and weave HIV intervention services with skills training and income generating programmes. We know that employment in this country is low, so young people cannot be expected to continue a healthy life without spaces where they can generate income for themselves, this will [in turn] reduce their vulnerability and dependency on older men.”

She added that government had to step up to what should always have been their role as Pepfar funding was never meant to substitute the work of government. Raphael said: “Pepfar was here to support the government in the early days of HIV. However, some of our government officials saw that as a way of evading their responsibility, and we are now here.”

Note: The Gates Foundation is mentioned in this article. Spotlight receives funding from the Gates Foundation, but is editorially independent – an independence that the editors guard jealously. Spotlight is a member of the South African Press Council and subject to the South African Press Code.

Republished from Spotlight under a Creative Commons licence.

Read the original article.

Categories : Substance UseTags :

Rates of Alcohol-induced Deaths Among the General Population Nearly Doubled from 1999 to 2024

On By ModernMedia

With females aged 25-34 showing a 255 percent surge in alcohol-related deaths during this time period

Credit: Pixabay CC0

In an analysis by race, sex, age, and geography, alcohol-induced death rates in 2024 are nearly double those in 1999, with a sharp increase at the onset of the COVID-19 pandemic. Although rates are higher for men, the largest increase in alcohol-induced deaths over the full 25-year period occurred in females aged 25-34, according to a study published on September 17 by Dr Tony Wong and colleagues at UCLA in the open-access journal PLOS Global Public Health.

Alcohol-induced deaths have been increasing over the past two decades. Particularly concerning are increases between 2019 and 2021, when the population was under significant stress from isolation due to the COVID-19 pandemic, and people with alcohol-use disorders were less able to access treatment. Quantifying mortality trends and determining whether alcohol-induced deaths have returned to pre-pandemic levels is essential for understanding long-term temporal patterns and dynamics. To examine these trends, the authors of this study analysed data from the Centers for Disease Control and Prevention’s National Vital Statistics System, focusing on 14 specific alcohol-induced causes of death.

Wong et al. found that rates of alcohol-induced deaths in the United States nearly doubled between 1999 and 2024, reaching their highest level in 2021. Most deaths are due to alcoholic liver disease and, to a lesser degree, alcohol-related mental and behavioural disorders. The largest overall increase in alcohol-induced mortality across all race, sex, age groups occurred in 2021 when fatalities peaked at 54,258 deaths overall. By 2024, fatalities had declined, but the average alcohol-induced mortality rate across U.S. counties remained approximately 25% higher than in 2019.

American Indian/Alaska Native populations (AIAN) remain the most affected, with male AIAN rates of alcohol-induced mortality three times higher than that of white males, and female AIAN mortality rates four times higher than that of white females, over the entire period of investigation.

The largest increase by demographic was among females aged 25-34, which rose from 0.9 deaths per 100 000 in 1999 to 3.2 per 100 000 in 2024 — a 255 percent increase. The second largest increase was in males aged 25-34, from 2.3 fatalities per 100 000 in 1999 to 6.5 in 2024 — a 188 percent increase. As deaths from chronic diseases related to alcohol use, such as certain cancers or cardiovascular events, were not included in this study, the overall fatality counts may be underestimated. These findings underscore the critical need for targeted policies to reduce excessive alcohol consumption and improve access to treatment for those who need it most.

Senior author Maria R D’Orsogna adds: “The rapid rise of alcohol-induced deaths among women is particularly concerning. Although men still die at higher rates, the gender gap appears to be closing. Notably, for the population aged 25-34, the male-to-female mortality ratio has decreased from three-to-one in 1999 to two-to-one in 2024.”

The authors conclude: “The rise in alcohol-induced mortality is widespread and affects the entire country, with particularly large surges arising during the COVID-19 pandemic. In the early months of the pandemic, alcohol-induced deaths among AIAN males increased by as much as 40% in a single month and remained unusually high for nearly four years. Similar trends were observed among AIAN and Black females, whose alcohol-induced death rates rose by over 30% in one month.”

Provided by PLOS

Categories : NeurologyTags :

Most Epilepsy Patients Wait a Year After Starting Treatment for Seizure Relief

On By ModernMedia
Source: Pixabay

Antiseizure medications help the majority of people with focal epilepsy, a common form of the neurological disorder. Yet most will still have episodes for at least a year after their treatment begins, until their doctors can find the right drug and dosage for them, a new study shows.

Accounting for about 60% of people with epilepsy, focal epilepsy occurs when nerve cells in a certain brain region send out a sudden, excessive burst of electrical signals. This uncontrolled activity, which is called a focal seizure, can cause problems such as abnormal emotions or feelings and unusual behaviours. Much attention has been paid to the minority of patients who do not respond well to available treatments, but the current study looks at another group: those who may not respond to the first medication or regimen prescribed but who might respond to another tried later.

Led by researchers at NYU Langone Health as part of the international Human Epilepsy Project, the study is among the first in a decade to focus on those whose seizures ultimately can be prevented or controlled with drugs. Results for nearly 450 men, women, and teens newly diagnosed with the disorder revealed that although more than half eventually received a medication or regimen that worked for them, major improvements were not achieved until an average of 12 months. Many needed even longer to find relief.

“Our findings suggest that those with focal epilepsy should expect a long adjustment period as their healthcare provider determines the best treatment regimen for them,” said study senior author and neurologist Jacqueline A. French, MD.

A possible explanation for this delay is that physicians are not selecting the ideal antiseizure therapy on their first try, adds Dr French, a professor in the Department of Neurology at the NYU Grossman School of Medicine and co-principal investigator of the Human Epilepsy Project.

Neurologists commonly start patients on levetiracetam, a drug that can target many types of seizures and has few interactions with other medications. Based on the new results, however, they may want to rethink this approach, says Dr French, noting that although 57% of the study participants were initially prescribed levetiracetam, only a quarter became seizure free on their first try.

A report on the findings appears in JAMA Neurology.

Thirty-four epilepsy centres in the United States, Europe, and Australia were involved in the study, which took place from 2012 to 2019. The team collected data about the patients’ medical histories, demographic factors, and the details of their epilepsy diagnoses. All were provided annual follow-ups for either three or six years.

During this time, participants tracked their seizure frequency in an electronic diary, describing each day as either “seizure-free” or “had a seizure.” The time, duration, and type of episode, along with other notes, were also recorded. The study volunteers also reported information about their antiseizure medications, noting the type, dose, and reasons for discontinuing a regimen.

Patients were considered seizure-free if they did not have an episode for at least a year (or longer if their seizures were infrequent).

The study further showed that together, 63% of all participants experienced ongoing or even worsening seizures during the first year of therapy, whether or not they would eventually find relief.

Notably, those who had seizures only a few times per year prior to treatment were more likely to respond to medication than those who had them weekly. In addition, participants with a history of psychological disorders such as anxiety and depression were almost twice as likely to resist the drugs than those without such a history.

“Our results show that the best way to a new treatment plan is sometimes through making better use of the tools we already have instead of always searching for the next breakthrough drug,” said Dr French, who is also a member of NYU Langone’s Comprehensive Epilepsy Center.

The researchers next plan to more closely examine those who did not become seizure-free during the study period, says Dr French.

Dr French cautions that the investigation did not directly assess the role of regimen choice, dose, or side effects on the way patients responded to treatment, and it did not exclude participants who failed to adhere to their prescribed regimen.

Source: NYU Langone Health

Categories : Metabolic Disorders Surgeries & ProceduresTags :

Study Shows Greater Long-Term Benefits of Bariatric Surgery Compared to GLP-1 RAs

On By ModernMedia
Sleeve gastrectomy. Credit: Scientific Animations CC4.0

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

Patients who had weight-loss surgery (also known as bariatric or metabolic surgery) lost more weight, achieved better blood sugar control, and relied less on diabetes and heart medications over 10 years. The research is published in Nature Medicine.

“Even with today’s best medicines, metabolic surgery offers unique and lasting benefits for people with obesity and diabetes,” said Ali Aminian, MD, director of Cleveland Clinic’s Bariatric & Metabolic Institute and primary investigator of the study. “The benefits we observed went beyond weight loss. Surgery was linked to fewer heart problems, less kidney disease, and even lower rates of diabetes-related eye damage.”

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications widely used to treat type 2 diabetes and obesity and to reduce health risks. Both metabolic surgery and GLP-1 medicines improve cardiovascular health and metabolism.

The M6 study (Macrovascular and Microvascular Morbidity and Mortality after Metabolic Surgery versus Medicines) followed 3932 adults with diabetes and obesity who received care at Cleveland Clinic for up to 10 years. Among them, 1657 underwent metabolic surgery (including gastric bypass or sleeve gastrectomy), while 2275 were treated with GLP-1 medicines (including liraglutide, dulaglutide, exenatide, semaglutide, and tirzepatide).

At the end of the study, patients who had metabolic surgery had a:

  • 32% lower risk of death
  • 35% lower risk of major heart problems (such as heart attack, heart failure, or stroke)
  • 47% lower risk of serious kidney disease
  • 54% lower risk of diabetes-related eye damage (retinopathy)

On average, people who had metabolic surgery lost 21.6% of their body weight over 10 years, compared with 6.8% weight loss in people who took GLP-1 medicines. Hemoglobin A1c, a marker of average blood sugar, improved more with surgery (-0.86%) than with GLP-1 medicines (-0.23%). Patients in the surgery group also required fewer prescriptions for diabetes, blood pressure, and cholesterol.

“Even in the era of these powerful new drugs to treat obesity and diabetes, metabolic surgery may provide additional benefits, including a survival advantage,” said Steven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic and senior author of the study.

“Our findings indicate that surgery should remain an important treatment option for obesity and diabetes,” said Dr Aminian. “These long-term benefits are harder to achieve with GLP-1 medicines alone, as many patients stop using the medications over time.”

According to the authors, the study has some limitations. It was observational rather than a randomized comparison of drugs and surgery, and it did not focus exclusively on the newest and most effective GLP-1 medicines. The researchers note that future studies should directly compare surgery with newer GLP-1 therapies, such as semaglutide and tirzepatide, to further guide treatment decisions.

Source: Cleveland Clinic

Categories : Environmental EffectsTags :

Wastewater Treatment Plants Are a Major Source of Pharmaceutical Pollution

On By ModernMedia

Common antidepressants, antibiotics and allergy drugs are being discharged into waterways, as conventional treatment fails to remove them

Photo by Myriam Zilles on Unsplash

Municipal wastewater treatment plants are ineffective at removing Prozac (fluoxetine) and other common pharmaceuticals in wastewater, causing the drugs to be discharged into lakes, rivers and streams where they pose a risk to aquatic organisms. Paulina Chaber-Jarlachowicz of the Institute of Environmental Protection – National Research Institute in Warsaw, Poland, and colleagues reported these findings in a new study published September 24, 2025 in the open-access journal PLOS One.

Most wastewater treatment plants break down organic compounds in wastewater using microbes, which are then removed as activated sludge. Existing research, however, suggests these methods do not remove pharmaceuticals effectively, causing them to be released into waterways. While some drugs do break down eventually, most persist in the environment, where they continue to be active, even at extremely low concentrations.

In the new study, researchers collected samples from six municipal wastewater treatment plants in Poland to investigate their ability to remove more than a dozen common pharmaceuticals. They measured the levels of drugs coming into the plant in the wastewater, determined how much is discharged to the environment in the treated water and sludge, and estimated the associated ecological risks.

The researchers found that all six wastewater treatment plants released pharmaceuticals into the environment. Only the pain reliever drugs naproxen (Aleve) and ketoprofen and the antihistamine salicylic acid were effectively removed during treatment.

For some pharmaceuticals, including the antidepressant fluoxetine (Prozac), the pain reliever diclofenac, and the anti-seizure drug carbamazepine, the treatment processes actually led to higher levels of the compounds in the discharged water than in the original wastewater. Fluoxetine and the allergy drug loratadine (Claritin) posed the greatest risk to aquatic organisms, due to their ability to disrupt hormone signaling and development at the levels seen in the treated water.

The new results add to the growing body of evidence demonstrating that conventional methods used by municipal wastewater treatment facilities are unable to remove many common drugs, making the plants a source of pharmaceutical pollution. These findings will lay the groundwork for further research into the inactivation of pharmaceutical compounds and their breakdown products in sewage and sludge.

The authors add: “The study’s findings demonstrated that municipal wastewater treatment facilities using conventional mechanical-biological processes (CAS) are ineffective at removing pharmaceuticals from wastewater. The annual emissions of pharmaceuticals to rivers from wastewater treatment plants in the study area amounted to at least 40Mg. Ketoprofen, sulfamethoxazole, carbamazepine and fluoxetine were identified as the primary contributors to the total mass load and emissions of pharmaceuticals.”

Provided by PLOS